#Switzerland #Basel #CordenPharma #Peptide Manufacturing #Basel Switzerland

CordenPharma’s Strategic Growth in Peptide Manufacturing

CordenPharma, a prominent name in pharmaceutical manufacturing, has announced an unprecedented investment exceeding €1 billion over the next three years aimed at expanding its peptide production capabilities across Europe and the USA. This landmark commitment is set to include more than €500 million allocated for a new facility dedicated to the development and production of peptides in the Basel region of Switzerland. This expansion is a significant part of CordenPharma's strategic efforts to enhance its operations and meet the growing global demand for peptide-based pharmaceuticals.

Investment Overview

Located in Muttenz, just eight kilometers from Basel, the new facility will serve as a cornerstone in CordenPharma's ambitious plan to bolster its peptide platform business. The company aims to surpass the €1 billion revenue mark from peptide services by 2028. This state-of-the-art plant is designed to accommodate both small and large-scale production needs, ensuring that CordenPharma maintains its leadership position in the market.

CordenPharma's current site in Colorado is also expanding. The enhancements there will allow for a doubling of existing peptide production capabilities, ensuring that CordenPharma can meet future demands effectively.

Reasons for Choosing Basel

Several strategic advantages influenced CordenPharma’s decision to establish the new plant near Basel. The region offers:

• - Robust Infrastructure: The existing systems for handling materials and processes essential for modern peptide production.
• - Optimal Logistics: Improved access to transport networks, streamlining distribution.
• - Established Supply Facilities: Significant resources already available to support the chemical industry.
• - Proximity to Talent: Access to a skilled workforce from the nearby biotech and pharmaceutical sectors in Europe’s leading innovation hub.
• - Sustainable Operations: The surrounding industrial park promises operational efficiency through closed material and energy loops and innovative waste recycling streams, aligning with CordenPharma’s sustainability goals.

Production Capacity and Technology

The new facility is poised to include multiple production lines, catering to small, medium, and large-scale peptide production. The facility will employ advanced Solid Phase Peptide Synthesis (SPPS) reactors with a cumulative capacity exceeding 5,000 liters, which will support both GLP-1 and Non-GLP-1 peptide projects.

Innovative automation and digital technologies will be integrated into the production process, facilitating adherence to stringent regulations, including BLA requirements. The construction and qualifying phases are scheduled from 2025 to 2027, with commercial operations expected to start in early 2028, potentially generating over 300 new jobs in the region.

Expanded Capabilities in the USA

As part of this initiative, the expansion efforts at CordenPharma’s facility in Boulder, Colorado, include upgrades to existing infrastructure and construction of new production areas on greenfield sites. This initiative aims to more than double the SPPS reactor capacity, bringing it to over 42,000 liters by 2028.

Leadership Insights

Dr. Michael Quirmbach, CEO of CordenPharma, expressed excitement about this strategic development, noting the facility’s design will enhance flexible and efficient peptide manufacturing to address the growing needs for innovative peptide medicines. Judith Charpentier, Co-Head Flagship Fund and Head of Healthcare at Astorg, emphasized the importance of CordenPharma's expansion to meet the increasing global demand for peptide manufacturing, highlighting their commitment to supporting the company in leveraging industrial excellence to strengthen its position as a leading Contract Development and Manufacturing Organization (CDMO).

Conclusion

With these significant investments, CordenPharma is well-positioned to enhance its production capabilities and remain at the forefront of the peptide manufacturing industry. The planned facility in Switzerland and the upgrades in Colorado are designed to not only meet existing demands but also to anticipate future challenges, ensuring that CordenPharma continues to provide critical peptide-based medications for patients worldwide. For more information, visit CordenPharma.